We provide business research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis covering the following parameters
- Technology evolution
- Research and development
- Existing market landscape
- Future Commercial potential
- Regulatory concerns
- Regional growth drivers
- Risks and opportunities
We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way. If you'd like us to do help you with your growing business needs, write to us and an expert will get in touch very shortly.
Targeted Protein Degradation Market, 2020 - 2030
The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Roots Analysis has not received any reviews.
Roots Analysis has not received any endorsements.